You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF Mutation

Showing 26 - 50 of 3,067
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

Active, not recruiting
  • BRAF V600E Mutation Present
  • +9 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2022

BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

Recruiting
  • BRAF NP_004324.2:p.V600M
  • +6 more
  • Portland, Oregon
    Providence Portland Medical Center
Aug 17, 2022

NSCLC Trial in Shanghai (HLX208)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai chest hospital
Jan 5, 2022

Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

Recruiting
  • Anaplastic Thyroid Cancer
  • ATC
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

Melanoma, Brain Metastases Trial in Canada (Dabrafenib, Trametinib)

Terminated
Has Results
  • Melanoma
  • Brain Metastases
  • Halifax, Nova Scotia, Canada
  • +5 more
Aug 18, 2021

CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

Recruiting
  • CRC
  • HLX208
  • Cetuximab Injection [Erbitux]
  • Shanghai, China
    Fudan University Affiliated Oncology Hospital
Dec 30, 2021

Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH Trial in Beijing (HLX208)

Recruiting
  • Langerhans Cell Histiocytosis
  • +3 more
  • Beijing, China
    Peking Union Medical College Hospital
Dec 30, 2021

Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

Not yet recruiting
  • Advanced Solid Tumor
  • BRAF V600 Mutation
  • Nanchang, Jiangxi, China
  • +2 more
Aug 12, 2022

Dabrafenib in Combination With Trametinib as Adjuvant Treatment

Recruiting
  • Melanoma
  • Zhengzhou, Henan, China
  • +6 more
Mar 17, 2022

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation Trial in Villejuif (Trametinib,

Active, not recruiting
  • Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
  • Villejuif, Val De Marne, France
    Gustave Roussy
Sep 27, 2021

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

Completed
Has Results
  • BRAF V600E Mutation
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 6, 2021

NSCLC Trial in China (Dabrafenib, Trametinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Harbin, Heilongjiang, China
  • +9 more
Jun 13, 2022

Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

Recruiting
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • +5 more
    • Aurora, Colorado
      University of Colorado, Cancer Center
    Nov 3, 2021

    Solid Tumor Trial in Beijing, Zhengzhou, Hangzhou (HL-085, Vemurafenib)

    Recruiting
    • Solid Tumor
    • Beijing, Beijing, China
    • +3 more
    Jan 20, 2022

    Cancer, Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

    Completed
    Has Results
    • Cancer
    • Melanoma
    • Guangzhou, Guangdong, China
    • +12 more
    Jan 4, 2022

    OPTImal PALliative Anti-epidermal Growth Factor Receptor

    Active, not recruiting
    • Colorectal Cancer Metastatic
    • +5 more
    • Plasma circulating DNA analysis
    • Aarhus, Denmark
      Aarhus University Hospital
    Feb 24, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

    Terminated
    • BRAF V600E Mutation Present
    • +7 more
    • Boston, Massachusetts
    • +1 more
    Mar 9, 2022

    Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

    Recruiting
    • Melanoma (Skin)
    • +2 more
      • Evora, Portugal
        Hospital Evora
      May 30, 2022

      Small Cell Lung Carcinoma Trial (Dabrafenib, Trametininb)

      Available
      • Small Cell Lung Carcinoma
      • (no location specified)
      Aug 20, 2021

      Cancer Trial in Worldwide (Dabrafenib, Trametinib, Panitumumab)

      Completed
      Has Results
      • Cancer
      • Scottsdale, Arizona
      • +19 more
      Sep 30, 2021

      Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation Trial in Tampa (Encorafenib Pill, Binimetinib Pill, Nivolumab)

      Recruiting
      • Melanoma Stage III
      • +2 more
      • Encorafenib Pill
      • +2 more
      • Tampa, Florida
        Moffitt Cancer Center
      May 27, 2022

      Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))

      Available
      • Pancreatic Cancer
      • +20 more
      • Ulixertinib (BVD-523)
      • Birmingham, Alabama
      • +25 more
      Nov 4, 2022

      BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma Trial in Czechia, Italy, Spain (Encorafenib + Binimetinib)

      Not yet recruiting
      • BRAF V600 Mutation
      • +3 more
      • Encorafenib + Binimetinib
      • Olomouc, Czechia
      • +5 more
      Sep 14, 2021

      Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

      Completed
      • Metastatic Melanoma
      • Palliative radiotherapy
      • Dabrafenib and trametinib (combination)
      • Darlinghurst, New South Wales, Australia
      • +2 more
      Apr 6, 2022